Integra LifeSciences Completes Acquisition of Salto Talaris(R) Total Ankle Replacement and Futura(TM) Silastic Toe Replacement Product Portfolios from Tornier N.V.
PLAINSBORO, N.J., Oct. 2, 2015 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it closed the acquisition of the United States rights to Tornier's Salto Talaris® and Salto Talaris® XT ankle replacement products and Tornier's Futura™ silastic toe replacement products.
"The addition of the Salto Talaris® enhances our lower extremities product offering and accelerates our entry into the U.S. total ankle replacement market," said Nick Gallucci, Integra's Vice President, U.S. Sales Leader, Extremity Reconstruction. "We are also pleased to welcome several key employees who will be joining Integra's commercial organization."
Integra expects the contribution to adjusted earnings per share to be immaterial during the first 12 months, given the normal sales transition and expected costs associated with the integration. Integra will provide further information on the expected revenues from the transaction on its third quarter earnings call.
About Integra
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for caregivers, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com
Integra's Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and reflect Integra's judgment as of the date of this release. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, Integra's ability to successfully integrate the acquired product lines into its own operations could affect the extent of the strategic benefits that Integra generates from this acquisition and the impact of the acquisition on results of operations, including revenue growth and earnings per share. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2014 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Integra LifeSciences Holdings Corporation
Investors:
Angela Steinway
(609) 936-2268
angela.steinway@integralife.com
Michael Beaulieu
(609) 750-2827
michael.beaulieu@integralife.com
Media:
Gianna Sabella
(609) 936-2389
gianna.sabella@integralife.com